Key highlights prompted Senseonics Haltings, Inc. (SENS), shares high in the after-hours

0
1356
BLNK
BLNK

Senseonics Haltings, Inc. (NYSE American: SENS), shares spiked 47.14% to $0.925 in the ‎after-hours session Wednesday. The company has officially revealed financial and ‎organizational modified products to design and commercialize long-term implantable ‎continuous glucose monitoring systems (CGM).‎

Get ‎the hottest stocks to trade every day before the market opens 100% ‎free. Click here ‎now. 

‎Latest Highlights


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


Net sales are projected to amount to around $3.5 million in the fourth quarter of 2020 and ‎rise from previous estimates by about $2.5 million.‎

Read More

The letter obtained from the FDA detailing agency personnel’s redislocation to fix COVID-19 ‎public health product authorization (EUA) concerns marketing applications, including the ‎Eversense 180-day product, which is being postponed by at least 60 days. Applications for ‎COVID-19 public health products Senseonics believes that this is consistent with other ‎medical technology firms’ findings.‎

Inclusion of Eversense Tier III CPT codes in the Practitioner Fee Schedule (PFS) 2021 Centers ‎for Medicare & Medicaid Programs (CMS), facilitating global payment for the purchase of ‎devices and procedural costs for healthcare providers across the U. S.‎

Net revenue is forecast to be within $12 and $15 million for the full year 2021, depending ‎on the installed base, accelerating Ascensia’s market operations, and other factors.‎

The deal was concluded with Roche to promote the distribution transfer to Ascensia, as ‎Roche sales end on 31 January 2021, comprising final orders, support activities for ‎transition, and settlement of other issues.‎‎

Get the hottest stocks to trade every day before the ‎market opens 100% ‎free. Click here now. 

‎By completing their ‎second lien loans to common equity, Highbridge’s second-lien loan was extinguished, ‎simplifying the United States’ financial structure.‎

LEAVE A REPLY

Please enter your comment!
Please enter your name here